Dave Jakob Lemus Insider Profile
4 Followers
Dave Jakob Lemus, Director at Silence Therapeutics, holds 7.53K shares in Silence Therapeutics (Ticker: SLN), holds 7.53K shares in Silence Therapeutics (Ticker: GB:SLN), holds ― shares in Morphosys (Ticker: GB:0NDV).
Dave Jakob Lemus's Trading History
| SLNSilence Therapeutics | Apr 19, 2021 | ― | Informative Buy | 5.01K | £40.27K | |
| 0NDVMorphosys | Jul 14, 2010 | ― | Uninformative Sell | 76.34K | ― | |
| SLNSilence Therapeutics | ― | Director | ― | $149.03K |
You May Also Like
Dave Jakob Lemus insider profile FAQ
What is the percentage of profitable transactions made by Dave Jakob Lemus?
The percentage of profitable transactions made by Dave Jakob Lemus is 100%.
What is the average return per transaction made by Dave Jakob Lemus?
The average return per transaction made by Dave Jakob Lemus is 85.40%.
What stocks does Dave Jakob Lemus hold?
Dave Jakob Lemus holds: SLN, GB:SLN, GB:0NDV stocks.
What was Dave Jakob Lemus's most profitable transaction?
Dave Jakob Lemus’s most profitable transaction was an Informative Buy of GB:SLN stock on October 4, 2019. The return on the trade was 127.30%.
What is Dave Jakob Lemus's role in Silence Therapeutics?
Dave Jakob Lemus's role in Silence Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
